Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers

BioEssays

Volumn 32, Issue 10, 2010, Pages 894-904

  Krutovskikh, Vladimir A ^a   Herceg, Zdenko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Biomarkers; Body fluids; Cancer; Cancer prevention; Epigenetics; Exosomes; MicroRNAs

Indexed keywords

MICRORNA; ONCOPROTEIN; TUMOR MARKER;

ANGIOGENESIS; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; DNA DAMAGE; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HUMAN; METASTASIS; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RNA TRANSCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

BODY FLUIDS; CARCINOGENS; EPIGENOMICS; EXOSOMES; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; NEOPLASMS; RNA, SMALL UNTRANSLATED; TUMOR MARKERS, BIOLOGICAL;

EID: 77957197569     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201000040     Document Type: Review

References (114)

1. Wong IHN, Lo YM. 2002. New markers for cancer detection. Curr Oncol Rep 4: 471-7.
2. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-54.
3. Chen X, Ba Y, Ma L, et al. 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
4. Lu M, Zhang Q, Deng M, et al. 2008. An analysis of human microRNA and disease associations. PLoS ONE 3: e3420.
5. Tie Y, Liu B, Fu H, et al. 2009. CirculatingmiRNA and cancer diagnosis. Sci China C Life Sci 52: 1117-22.
6. Xi Y, Nakajima G, Gavin E, et al. 2007. Systematic analysis ofmicroRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13: 1668-74. (Pubitemid 47481675)
7. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-69.
8. Croce CM. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-14.
9. Schickel R, Boyerinas B, Park SM, et al. 2008. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27: 5959-74.
10. Hernando E. 2007. microRNAs and cancer: role in tumorigenesis, patient classification and therapy. Clin Transl Oncol 9: 155-60.
11. Manikandan J, Aarthi JJ, Kumar SD, et al. 2008. Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation 2: 330-4.
12. Sassen S, Miska EA, Caldas C. 2008. MicroRNA: implications for cancer. Virchows Arch 452: 1-10.
13. Hammond SM. 2006. MicroRNAs as oncogenes. Curr Opin Genet Dev 16: 4-9.
14. Cho WC. 2007. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6: 60.
15. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-97.
16. Berezikov E, Guryev V, van de Belt J, et al. 2005. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120: 21-4. (Pubitemid 40094599)
17. Rigoutsos I, Huynh T, Miranda K, et al. 2006. Short blocks from the noncoding parts of the human genome have instances within nearly all known genes and relate to biological processes. Proc Natl Acad Sci USA 103: 6605-10.
18. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. 2006. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-4.
19. Griffiths-Jones S, Saini HK, van Dongen S, et al. 2008. miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-8.
20. Zeng Y. 2006. Principles of micro-RNA production and maturation. Oncogene 25: 6156-62.
21. Yi R, Qin Y, Macara IG, et al. 2003. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17: 3011-6.
22. Doench JG, Petersen CP, Sharp PA. 2003. siRNAs can function as miRNAs. Genes Dev 17: 438-42.
23. Zeng Y, Yi R, Cullen BR. 2003. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100: 9779-84.
24. Nilsen TW. 2007. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23: 243-9.
25. Betel D, Wilson M, Gabow A, et al. 2008. The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-53.
26. Sethupathy P, Corda B, Hatzigeorgiou AG. 2006. TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA 12: 192-7. (Pubitemid 43121923)
27. Krek A, Grun D, Poy MN, et al. 2005. Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
28. Chen K, Rajewsky N. 2006. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 38: 1452-6.
29. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked, by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
30. Gardner PP, Vinther J. 2008. Mutation of miRNA target sequences during human evolution. Trends Genet 24: 262-5.
31. Sethupathy P, Collins FS. 2008. MicroRNA target site polymorphisms and human disease. Trends Genet 24: 489-97.
32. Rigoutsos I. 2009. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res 69: 3245-8.
33. Chi SW, Zang JB, Mele A, et al. 2009. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460: 479-86.
34. Saini HK, Griffiths-Jones S, Enright AJ. 2007. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 104: 17719-24.
35. Fabbri M, Garzon R, Cimmino A, et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-10.
36. Garzon R, Liu S, Fabbri M, et al. 2009. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113: 6411-8.
37. Tuddenham L, Wheeler G, Ntounia-Fousara S, et al. 2006. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett 580: 4214-7.
38. Varambally S, Cao Q, Mani RS, et al. 2008. Genomic loss ofmicroRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-9.
39. Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931-4.
40. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
41. Kumar MS, Lu J, Mercer KL, et al. 2007. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-7. (Pubitemid 46676103)
42. Volinia S, Calin GA, Liu CG, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-61.
43. Yanaihara N, Caplen N, Bowman E, et al. 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-98.
44. Yu SL, Chen HY, Chang GC, et al. 2008. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57.
45. Hui AB, Shi W, Boutros PC, et al. 2009. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89: 597-606.
46. Iorio MV, Ferracin M, Liu CG, et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-70.
47. Sarver AL, French AJ, Borralho PM, et al. 2009. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401.
48. Schetter AJ, Leung SY, Sohn JJ, et al. 2008. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-36.
49. Yu Yao A-LS, Zong-Fang Li, Li-Ying Liu, et al. 2009. MicroRNA profiling of human gastric cancer. Mol Med Rep 2: 963-970.
50. Jiang J, Gusev Y, Aderca I, et al. 2008. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14: 419-27.
51. Wang Y, Lee AT, Ma JZ, et al. 2008. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283: 13205-15.
52. Murakami Y, Yasuda T, Saigo K, et al. 2006. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-45.
53. Schaefer A, Jung M, Mollenkopf HJ, et al. 2010. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-76.
54. Porkka KP, Pfeiffer MJ, Waltering KK, et al. 2007. MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-5.
55. Siva AC, Nelson LJ, Fleischer CL, et al. 2009. Molecular assays for the detection of microRNAs in prostate cancer. Mol Cancer 8: 17.
56. Ozen M, Creighton CJ, Ozdemir M, et al. 2008. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-93. (Pubitemid 351380263)
57. Lee EJ, Gusev Y, Jiang J, et al. 2007. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-54.
58. Bloomston M, Frankel WL, Petrocca F, et al. 2007. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-8.
59. Iorio MV, Visone R, Di Leva G, et al. 2007. MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-707.
60. Ruebel K, Leontovich AA, Stilling GA, et al. 2010. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 23: 367-75.
61. Liu X, Chen Z, Yu J, et al. 2009. MicroRNA profiling and head and neck cancer. Comp Funct Genomics 2009: 837514.
62. Jung M, Mollenkopf HJ, Grimm C, et al. 2009. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13: 3918-28.
63. Calin GA, Ferracin M, Cimmino A, et al. 2005. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-801.
64. Wong TS, Liu XB, Wong BY, et al. 2008. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: 2588-92.
65. Chang T-C, Yu D, Lee Y-S, et al. 2008. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Gen 40: 43-50.
66. Sachdeva M, Zhu S, Wu F, et al. 2009. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207-12.
67. Fassan M, Baffa R, Palazzo JP, et al. 2009. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 11: R58.
68. Blenkiron C, Goldstein LD, Thorne NP, et al. 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
69. Nikiforova MN, Tseng GC, Steward D, et al. 2008. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93: 1600-8. (Pubitemid 351656494)
70. Catto JW, Miah S, Owen HC, et al. 2009. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69: 8472-81.
71. Hurst DR, Edmonds MD, Welch DR. 2009. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69: 7495-8.
72. Lujambio A, Calin GA, Villanueva A, et al. 2008. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105: 13556-61.
73. Calin GA, Sevignani C, Dumitru CD, et al. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004.
74. Zhang L, Huang J, Yang N, et al. 2006. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103: 9136-41.
75. Shen J, Ambrosone CB, DiCioccio RA, et al. 2008. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 29: 1963-6.
76. Mayer C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-9.
77. Lee YS, Dutta A. 2007. The tumor suppressormicroRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-30. (Pubitemid 46686471)
78. Toyota M, Suzuki H, Sasaki Y, et al. 2008. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68: 4123-32.
79. Lujambio A, Ropero S, Ballestar E, et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67: 1424-9.
80. Brueckner B, Stresemann C, Kuner R, et al. 2007. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67: 1419-23.
81. Nasser MW, Datta J, Nuovo G, et al. 2008. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-405.
82. Datta J, Kutay H, Nasser MW, et al. 2008. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049-58.
83. Lehmann U, Hasemeier B, Christgen M, et al. 2008. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214: 17-24.
84. Kondo N, Toyama T, Sugiura H, et al. 2008. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68: 5004-8.
85. Saito Y, Liang G, Egger G, et al. 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-43.
86. Kozaki K, Imoto I, Mogi S, et al. 2008. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68: 2094-105. (Pubitemid 351521781)
87. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. 2009. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69: 4443-53.
88. Scott GK, Mattie MD, Berger CE, et al. 2006. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66: 1277-81.
89. Merritt WM, Lin YG, Han LY, et al. 2008. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-50.
90. Flavin RJ, Smyth PC, Finn SP, et al. 2008. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 21: 676-84.
91. Chiosea S, Jelezcova E, Chandran U, et al. 2006. Up-regulation of Dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 169: 1812-20.
92. Tokumaru S, Suzuki M, Yamada H, et al. 2008. let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis 29: 2073-7.
93. Suzuki HI, Yamagata K, Sugimoto K, et al. 2009. Modulation of microRNA processing by p53. Nature 460: 529-33.
94. He L, He X, Lim LP, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-4.
95. Chang TC, Wentzel EA, Kent OA, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-52.
96. Bommer GT, Gerin I, Feng Y, et al. 2007. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-307.
97. Le MT, Teh C, Shyh-Chang N, et al. 2009. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23: 862-76.
98. Ye Y, Wang KK, Gu J, et al. 2008. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res 1: 460-9.
99. Huang Z, Huang D, Ni S, et al. 2010. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118-26.
100. Ng EK, Chong WW, Jin H, et al. 2009. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58: 1375-81.
101. Rabinowits G, Gercel-Taylor C, Day JM, et al. 2009. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-6.
102. Taylor DD, Gercel-Taylor C. 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21. (Pubitemid 351853251)
103. Mitchell PS, Parkin RK, Kroh EM, et al. 2008. CirculatingmicroRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-8.
104. Lodes MJ, Caraballo M, Suciu D, et al. 2009. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 4: e6229.
105. Wang J, Chen J, Chang P, et al. 2009. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2: 807-13.
106. Tanaka M, Oikawa K, Takanashi M, et al. 2009. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 4: e5532.
107. Gilad S, Meiri E, Yogev Y, et al. 2008. Serum microRNAs are promising novel biomarkers. PLoS ONE 3: e3148.
108. Nilsson J, Skog J, Nordstrand A, et al. 2009. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 100: 1603-7.
109. Valadi H, Ekstrom K, Bossios A, et al. 2007. Exosome-mediated transfer of mRNAs andmicroRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-9.
110. Skog J, Wurdinger T, van Rijn S, et al. 2008. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-6.
111. Al-Nedawi K, Meehan B, Micallef J, et al. 2008. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10: 619-24.
112. Schembri F, Sridhar S, Perdomo C, et al. 2009. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci USA 106: 2319-24.
113. Kovalchuk O, Filkowski J, Meservy J, et al. 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-9.
114. Persson H, Kvist A, Vallon-Christersson J, et al. 2009. The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol 11: 1268-71.